ENANTA PHARMACEUTICALS INC
Qualité des données : 100%
ENTA
NASDAQ
Manufacturing
Chemicals
14,11 €
▲
0,16 €
(1,15%)
Cap. Boursière: 403,37 M
Prix
13,90 €
Cap. Boursière
403,37 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Revenue declined -9,43% annually over 5 years
Negative free cash flow of -44,01 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 6,01%
Croissance
Revenue Growth (5Y)
-9,43%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)-3,42%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-91,15%
En dessous de la moyenne du secteur (-53,58%)
ROIC-28,20%
Net Margin-111,78%
Op. Margin-115,09%
Sécurité
Debt / Equity
N/A
Current Ratio4,44
Interest Coverage-8,97
Valorisation
PE (TTM)
-4,30
En dessous de la moyenne du secteur (-1,48)
P/B Ratio3,19
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1366 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1366 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -4,3 | -1,5 |
| P/B | 3,2 | 1,6 |
| ROE % | -91,2 | -53,6 |
| Net Margin % | -111,8 | -41,5 |
| Rev Growth 5Y % | -9,4 | 1,8 |
| D/E | — | 0,3 |
Objectif de Cours des Analystes
6 analystes
Buy
Actuel
14,11 €
Objectif
18,50 €
12,00 €
20,00 €
20,00 €
Prévisions
P/E Prévisionnel
-6,39
BPA Prévisionnel
-2,21 €
CA Est.
65,87 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-2,21 €
-3,08 € – -1,60 €
|
65,87 M | 5 |
| FY2026 |
-2,13 €
-2,55 € – -1,31 €
|
66,40 M | 4 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-0,49 €
-0,67 € – -0,25 €
|
16,92 M | 4 |
| 2026 Q1 |
-0,51 €
-0,65 € – -0,32 €
|
16,82 M | 4 |
Surprises de Résultats
Derniers 5 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -0,88 € | -0,42 € | +52,1% |
| Q32025 | -1,01 € | -0,87 € | +13,9% |
| 2026-Q1 | -0,51 € | -0,42 € | +17,2% |
| Q22025 | -0,89 € | -0,85 € | +4,0% |
| Q12025 | -1,14 € | -1,06 € | +6,7% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -3,42% | Revenue Growth (3Y) | -9,18% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -9,43% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 83,94 M | Net Income (TTM) | -93,83 M |
| ROE | -91,15% | ROA | -29,76% |
| Gross Margin | N/A | Operating Margin | -115,09% |
| Net Margin | -111,78% | Free Cash Flow (TTM) | -44,01 M |
| ROIC | -28,20% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4,44 |
| Interest Coverage | -8,97 | Asset Turnover | 0,27 |
| Working Capital | 153,96 M | Tangible Book Value | 126,59 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -4,30 | Forward P/E | N/A |
| P/B Ratio | 3,19 | P/S Ratio | 4,81 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -10,91% | ||
| Market Cap | 403,37 M | Enterprise Value | 365,93 M |
| Per Share | |||
| EPS (Diluted TTM) | -4,26 | Revenue / Share | 2,89 |
| FCF / Share | -1,52 | OCF / Share | -1,07 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 15,53% | FCF Conversion | 46,91% |
| SBC-Adj. FCF | -67,77 M | Growth Momentum | 6,01 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 65,32 M | 67,64 M | 79,20 M | 86,16 M | 97,07 M |
| Net Income | -81,89 M | -116,05 M | -133,82 M | -121,76 M | -79,00 M |
| EPS (Diluted) | -3,84 | -5,48 | -6,38 | -5,91 | -3,92 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -85,35 M | -121,69 M | -137,21 M | -123,84 M | -109,57 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 106,74 M | 131,48 M | 163,52 M | 164,52 M | 174,11 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 4,59 M | 2,34 M | 2,37 M | 2,97 M | 3,33 M |
| Interest Expense | 7,68 M | 10,94 M | 5,15 M | — | — |
| Income Tax | -1,66 M | -1,74 M | 2,82 M | -433 000,0 | -28,58 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 280,73 M | 376,65 M | 462,28 M | 375,41 M | 438,79 M |
| Total Liabilities | 216,02 M | 247,84 M | 245,54 M | 54,08 M | 39,36 M |
| Shareholders' Equity | 64,72 M | 128,81 M | 216,74 M | 321,33 M | 399,43 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 32,30 M | 37,23 M | 85,39 M | 43,99 M | 57,21 M |
| Current Assets | 204,34 M | 299,85 M | 422,79 M | 311,71 M | 319,02 M |
| Current Liabilities | 48,56 M | 57,54 M | 62,79 M | 29,83 M | 36,17 M |
{"event":"ticker_viewed","properties":{"ticker":"ENTA","listing_kind":"stock","pathname":"/stocks/enta","exchange":"NASDAQ","country":"US"}}